Page 2 - Lorem Foundation News Today

Part one of a two-part series covering highlights from the Galien Forum in New York City, held on October 27.


/PRNewswire/ -- The Prix Galien USA Committee honored excellence and innovation in life sciences during the Prix Galien USA Forum and 16th annual Prix Galien...

SAN DIEGO, Sept. 04, 2022 (GLOBE NEWSWIRE) -- OTS is pleased to announce that, after two years of meeting virtually, the 18th Annual Oligo Meeting will...

Investegate announcements from Oligonucleotide Therapeutics S, The Oligonucleotide Therapeutics Societys Highly Anticipated Annual Meeting Returns in Person This Year

A new initiative, Silence ALS, will develop experimental personalized therapies to treat patients with rare genetic forms of ALS (also known as Lou Gehrig's disease).

NEW YORK, May 10, 2022 /PRNewswire/ -- The global pharmacovigilance market is expected to reach $15,259.8 million by 2030 from $6,724.2 million in 2021, growing at a CAGR of 9.5% during 2021-2030

N-Lorem Foundation and Columbia University Establish Silence ALS Initiative - read this article along with other careers information, tips and advice on BioSpace

Some ultra-rare diseases have fewer than 30 known patients globally. Is there an ethical and economical way to test and approve treatments?

Parexel to provide clinical operations, real-world data solutions and expertise including medical and regulatory alongside innovative clinical research tools

Press release content from Business Wire. The AP news staff was not involved in its creation.